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Abstract
Background: Local control is always considered in metastatic neuroblastoma (NBL). The aim of this study is to
evaluate the impact of radical surgery on survival in children over 1 year of age.
Methods: Fifty-eight patients older than 1 year of age with metastatic NBL were treated with conventional plus
high-dose chemotherapy with or without addition of local radiotherapy (RT, 21Gy). Surgery was classified as radical
surgery (complete resection and gross total resection) or non-radical surgery. The Kaplan-Meier method and the
Cox proportional hazard model were used to calculate the probability of progression free and overall survival (PFS
and OS) and for multivariate analysis.
Results: The 5-year PFS and OS for patients with radical surgery were 26% (95% CI 14-40%) and 38% (95% CI 23-53%)
respectively, while the PFS and OS for patients without radical surgery were 33% (95% CI 10-59%) and 31% (95% CI
10-55%) (respectively, P 0.85 and P 0.42). The 5-year PFS and OS for patients who received RT were 36% (95% CI
19-53%) and 46% (95% CI 26-64%) respectively, while the 5-year PFS and OS for patients who did not receive RT were
22% (95% CI 9-38%) and 27% (95% CI 13-42%) respectively (P 0.02 for PFS). Multivariate analysis confirmed the role of
well-known prognostic factors, such as the presence of MYCN amplification, age and response before high-dose
chemotherapy.
Conclusions: Our data suggest that the degree of resection does not influence survival in metastatic NBL patients
treated with high-dose chemotherapy; local RT contributes to local disease control.
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Background
Neuroblastoma (NBL) is the most common solid extra-
cranial tumor of childhood. The clinical course varies
from spontaneous tumor regression to an aggressive,
poorly responding disease, depending on patient age at
diagnosis, metastatic dissemination and MYCN status [1].
Despite intensive treatment, the outcome of high-risk
NBL (i.e. metastatic disease or patients with MYCN ampli-
fication) remains unsatisfactory: the reported 3-year event-
free survival (EFS) is less than 40% in many studies [1-6].
Currently, standard treatment for high-risk NBL is based
on intensive systemic chemotherapy, surgery on primary
tumor, high-dose chemotherapy followed by autologous
bone marrow transplantation (ABMT) and/or peripheral
blood stem cell transplantation (PBSC), radiotherapy (RT)
on primary tumor bed and differentiating/immunotherapy
treatment [1-6]. Local control of NBL, based on surgery
and RT on primary site, is considered a valuable option in
most international protocols. Nevertheless, the impact of
surgery on survival in metastatic NBL treated with an
intensive approach remains controversial [7-15]. Some
authors reported a favorable outcome in patients who
undergo gross total resection (i.e. >95%) of the primary
tumor [7-11]; others failed to show an improvement in
survival rate after radical surgical excision [12-15]. How-
ever, several studies suggested that RT contributes signifi-
cantly to the prevention of local relapse [16-18].
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The aim of this study was to analyze the role of sur-
gery in a series of metastatic NBL in children over 1 year
of age diagnosed and treated at the Ospedale Pediatrico
Bambino Gesù (OPBG). All patients were treated ac-
cording to two previously published local protocols
based on conventional chemotherapy followed by high-
dose chemotherapy [19-21].
Methods
Children over one year of age with metastatic NBL
were classified as having high-risk disease and were en-
rolled in two consecutive institutional protocols from
July 1996 to August 2009. The first protocol was identi-
fied as ICE/CECAT [18] and the second as TopoNB
[19]. The ICE/CECAT protocol consisted of two courses
of ifosfamide/carboplatin/etoposide (ICE), two courses of
cyclophosphamide/etoposide/carboplatin/thiotepa (CECAT)
or two further ICE courses.
The Topo/NB protocol consisted of two courses of
topotecan/cyclophosphamide followed by two courses of
ifosfamide/carboplatin/etoposide (ICE) and a later course
of cyclophosphamide/doxorubicin/vincristine. The Ethical
Committee of Ospedale Pediatico Bambino Gesù IRCCS
(ref number 62,10; May, 17th 2010) approved both proto-
cols, as well as this retrospective study. Written informed
consent was obtained from the children’s parents or legal
guardians. Both protocols were based on conventional in-
duction chemotherapy, surgery on primary tumor and
high-dose chemotherapy followed by PBSC rescue and/or
ABMT plus 9-cis retinoic acid as previously reported
[18-21]. In the second and more recent protocol, the treat-
ment was completed by local RT with 21 Gy on tumor
bed before surgery [17].
Surgical resection of primary tumor was performed ei-
ther at diagnosis or after the 4th or 5 th course of
chemotherapy. In detail, patients with tumors considered
to be resectable at diagnosis underwent primary surgery,
while patients with unresectable tumor at diagnosis and
without disease progression after induction chemother-
apy underwent delayed surgery.
The same surgical team performed the surgery in all
patients. The surgical and pathology reports and imaging
before and after surgery, were reviewed for this study.
Surgery was classified as “radical” or “not radical”. The
“radical” group included patients who had undergone
complete resection with no visible tumor or at least a
gross total resection (GTR) with less than 5% of visible
tumor. The “not radical” group included patients who
had undergone a partial resection (PR) with more than
50% tumor volume removal or biopsy only.
Evaluation of disease
Primary tumor evaluation was done by computed tom-
ography (CT) or magnetic resonance imaging (MRI).
Metastatic spread was assessed by total body CT scan
and 123-iodine metaiodobenzylguanidine (123I-MIBG)
scintigraphy and completed by two bilateral trephines
and bone marrow aspirates. Diagnosis and staging were
performed according to the International Neuroblastoma
Diagnosis and Staging Criteria [22]. Primary tumor re-
sponse was evaluated using the same investigations as
those employed at diagnosis. Responses were assessed
according to the International Neuroblastoma Response
Criteria [22].
Statistical analysis
Progression-free survival (PFS) was defined as the time
interval from the date of diagnosis to the date of first re-
lapse/progression or the date of the last follow-up for
surviving patients. Overall survival (OS) was defined as
the time interval between the date of diagnosis and the
date of death from any cause or the date of last follow-
up for surviving patients. Local progression-free survival
(LPFS) was defined as the time interval between the date
of diagnosis and the date of first local relapse/progression
or the date of the last follow-up. The Kaplan–Meier
method was used to estimate survival curves [23], while
the log-rank test was used to compare differences between
groups. Multivariate analyses were performed using Cox
proportional hazards regression model for PFS and OS.
All variables with P values >0.2 in univariate analysis were
included in the initial model and were then eliminated
one at a time in a stepwise fashion to retain only those
variables that reached a P value of 0.05 or less in the final
models. All P values were 2-sided, with a type-I error
rate fixed at 0.05. Variables considered as potentially
influencing PFS and OS were: age (either >18 months
or <18 months), site of primary tumor, site of metasta-
sis (bone/bone marrow/lymph node or lymph node
alone or others), MYCN status (MYCN amplified ver-
sus MYCN non amplified or MYCN gain), induction
regimen, response before surgery, RT, response at the
end of induction and quality of surgery, defined as radical
or non-radical surgery. Analyses were performed using
the Stata 9.0 statistical software package (StataCorp LP,
TX, USA).
Results
This study evaluated 58 children over one year of age di-
agnosed with metastatic NBL at the OPBG and enrolled
into two local treatment protocols. Patient characteris-
tics are summarized in Table 1. Median age at diagnosis
was 36 months (range 13–216), 11 of the 58 patients
(19%) being younger than 18 months. Surgery was per-
formed at diagnosis in 7 patients and was radical in 6 of
them. In 47 (81%) patients tumor resection was per-
formed after induction chemotherapy and was complete
in 39 (83%). MYCN status was available for 56 patients;
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out of 43 patients with radical surgery, 13 presented
MYCN amplification while 6 patients out of 13 without
radical surgery had MYCN amplification (P 0.29).
In this series, there was no intraoperative death; one
patient died after surgery due to acute renal failure.
Nephrectomy was performed in 7 patients (13%), polar
nephrectomy for renal NBL and partial liver removal
in one patient each. Post-surgery abscess, massive
blood loss (defined as loss of one blood volume in
24 hours, or 50% loss of one blood volume in 3 hours,
or losses over 1,45 ml/kg/min for 20 minutes, or trans-
fusion of over > 40 ml/kg of red cells) [24,25], or the
need for mechanical ventilation for more than 5 days
were not recorded.
Survival
The median follow-up for the entire cohort was 45 months
(range 1 month-16 years). The 5-year PFS and OS were
28% (95% CI 17-40%) and 36% (95% CI 24-49%), respect-
ively, while the 5-year LPFS was 72% (CI 25-83%). Out of
58 patients, 41 (71%) died at a median time from diagnosis
of 28 months (range 1–94 months): 39 died due to re-
lapsed/resistant disease and two from complications (the
patient who died of renal failure after surgery and one
who died due to acute bleeding after accidental removal of
the central venous catheter). Relapse/progression occurred
in 39/58 (67%) patients after a median time from diagnosis
of 15 months (range 6–49 months). Local relapse occurred
in 12/58 (20%) patients; none of them had received RT,
while radical surgery had been performed in 10 of the 12
patients. Local relapse was observed in 7 out of 19 (37%)
patients with MYCN-amplified tumor, while relapses were
recorded in only 5 out of 37 (14%) patients with non-
MYCN-amplified tumors (P < 0.005). The 5-year PFS and
OS for patients with radical surgery were 26% (95% CI 14-
40%) and 38% (95% CI 23-53%) respectively, while the PFS
and OS for patients without radical surgery were 33%
(95% CI 10-59%) and 31% (95% CI 10-55%) (P 0.85 for
PFS and P 0.42 for OS, (Figures 1 and 2). The 5-year PFS
and OS for patients who did or did not receive RT were
36 % (95% CI 19-53%) and 46% (95% CI 26-64%) respect-
ively, and 22% (95% CI 9-38%) and 27% (95% CI 13-43%)
respectively (P < 0.02 for PFS and P = 0.23 for OS).
On univariate analysis, age, site of metastasis, MYCN
status, response before high-dose chemotherapy and RT
were factors influencing patient outcome (See Table 2
for more details). The final model of the multivariate
analysis showed age, MYCN status and response before
high-dose chemotherapy to be prognostic factors for
Table 1 Patient characteristics
N %
Age Median (months) 36
Range (months) 13-216
Gender Male 35 60
Female 23 40
Site of Metastasis Bone/Bone Marrow/
Lymph node
48 83
Lymph node alone 3 5
Others 7 12
Primary Sites Retroperitoneal 12 21
Adrenal Gland 41 71
Thorax 5 8
MYCN Amplified 19 34
(available for 56 pt) Non amplified or
MYCN gain
37 66
Induction CT ICE/CECAT 21 36




>50%, <95% 34 68
>95% 12 24
Surgery Radical 45 78
Not Radical 13 22
Response before HDC** CR/VGPR 21 37
PD 11 20
PR 24 43
RT Yes 28 48
No 30 52
LEGEND: pt, patient; BX, biopsy; CR, complete remission; VGPR, very good
partial remission; PD, progressive disease; PR, partial response. For “others” site
of metastasis was considered Bone or/and Bone Marrow or/and Lymph node
plus lung or/and liver metastatis.
*In 7 patients surgery was performed at diagnosis, one patient died for an
acute bleeding after accidental removal of central vein catheter.
**Two patients were not considered for this analysis; one patient died for
acute bleeding and the later one died for acute renal failure.
Figure 1 Progression Free Survival (PFS) and Overall Survival
(OS) of the whole population.
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PFS and OS. MYCN amplification was associated with
poor OS (HR 2.24, P = 0.043) as 183 were age >18 months
(HR 4.52, P = 0.042) and Progressive Disease (PD) at the
end of induction (HR 5.75, P < 0.001). Moreover, in this
series RT was a protective factor for OS; patients who did
not receive RT presented an HR of 2.36 (P = 0.025) for
OS. Response before high-dose chemotherapy was shown
to be the major prognostic factor for PFS; patients with
PR presented an HR of 3.15, P = 0.006. Regarding LPFS,
response before high-dose chemotherapy, RT and MYCN
status were found to be the major prognostic factors. The
5-year LPFS in patients who did or did not receive RT was
100% and 48% (95% CI 27-67%) respectively (P <0.001)
(see also Table 3 for more details). In the final model of
multivariate analysis, MYCN amplification was shown to
be a prognostic factor for local recurrence with an HR of
2.16 and P = 0.043.
Figure 2 Local Progression Free Survival (PFS) and PFS of whole
population and by surgery; Overall Survival (OS) by surgery.
Table 2 Univariate analysis of outcome’s predictive factors
Pts PFS 5 years 95% CI Univariate
analysis
OS 5 years 95% CI Univariate
analysis
% P value % P value
Age 12-18 months 11 64 30-85 0.01 73 37-90 0.03
>18 months 47 19 9-32 28 16-41
Site of Metastasis Bone/Bone Marrow/Lymph-node 48 25 14-39 0.03 35 22-49 0.03
Lymph-node alone 3 100 - 100 -
Others 7 14 1-46 14 1-46
Primary Sites Retroperitoneal 12 17 3-41 0.28 11 1-38 0.21
Adrenal Gland 41 28 15-42 40 25-55
Thorax 5 60 13-88 60 13-88
MYCN Amplified 19 30 11-52 0.24 26 10-47 0.00
(available for 56 pt) Non amplified or MYCN gain 37 29 16-44 44 27-59
Induction CT ICE/CECAT 21 20 6-39 0.59 29 12-48 0.19
Topo NB 37 33 19-49 40 24-56
Primary Tumor Reduction
before Surgery*
<50% 35 22 9-38 0.52 38 21-54 0.43
>50%, <90% 4 0 - 0 -
>90% 12 33 10-59 33 10-59
Surgery Radical 45 26 14-40 0.85 38 23-52 0.42
Not Radical 13 33 10-59 31 10-55
Response before HDC** CR/VGPR 21 62 38-79 <0.001 65 40-82 <0.001
PD 11 0 - 10 1-33
PR 24 13 3-29 29 13-48
RT Yes 28 36 19-53 0.23 46 26-64 0.02
No 30 22 9-38 27 13-43
LEGEND: pt, patient; BX, biopsy; CR, complete remission; VGPR, very good partial remission; PD, progressive disease; PR, partial response.
*In 7 patients surgery was performed at diagnosis, one patient died for an acute bleeding after accidental removal of central vein catheter.
**Two patients were not considered for this analysis; one patient died for acute bleeding and the later one died for acute renal failure.
Progression-Free Survival and Overall Survival according to predictive factors.
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Discussion
Treatment of metastatic NBL in children over 1 year of age
continues to represent a challenge for pediatric oncologists.
Local control is always considered in the therapeutic strat-
egy for children with metastatic NBL; however, its role in
the treatment of patients receiving high-dose chemother-
apy remains a subject of medical debate [26]. In this series
of homogeneously treated metastatic NBL, the quality of
surgery had no impact on survival. Indeed, the PFS and OS
of patients who underwent radical surgery were compar-
able with those of patients with partial removal of primary
tumor or biopsy only. Multivariate analysis showed that
previously identified prognostic factors, i.e. MYCN amplifi-
cation, age at diagnosis and response at the end of the in-
duction phase, represented the major prognostic factors in
the patient cohort.
This is the first single-center report on the impact of
local control in terms of survival in patients treated with
high-dose chemotherapy. Previously published data re-
ported on patients enrolled in studies - mostly multi-
center studies - with randomization between high-dose
chemotherapy and conventional therapy, or with differ-
ent post-induction treatments [7-15].
There are still conflicting reports in the literature con-
cerning the role of radical surgery [26]. Some Authors
reported the absence of any advantage in terms of sur-
vival probability for patients with CR of the primary
tumor, as it is almost impossible to achieve a complete
absence of microscopic residual disease on the tumor
bed [27]. However, in a single center study analyzing
cases diagnosed over more than 20 years, LaQuaglia et al.
noted that gross tumor resection correlated with an im-
proved outcome in terms of both local control and OS
[8]. In a single center study, McGregor et al. observed
an advantage for gross total resection in terms of sur-
vival [11]. In both these series [8,11], patients received
different post-induction treatments.
Adkins et al. [9] showed a trend toward improved sur-
vival for complete resection in high risk NBL treated ac-
cording to the CCG-3891 study. This study included
metastatic patients over 1 year of age and patients with lo-
calized MYCN-amplified tumor. The randomized CCG-
Table 3 Univariate analysis of factors predictive for Local PFS
Pts Local PFS 95% CI Univariate analysis
% P value
Age 12-18 months 11 100 - 0.04
>18 months 47 63 42-76
Site of Metastasis Bone /Bone Marrow/ Lymph-node 48 75 56-86 0.07
Lymph-node alone 3 100 -
Others 7 27 1-69
Primary Sites Retroperitoneal 12 59 16-86 0.50
Adrenal Gland 41 76 55-88
Thorax 5 60 13-88
MYCN Amplified 19 51 23-74 0.00
(available for 56 pt) Non-amplified or MYCN gain 37 80 59-91
Inducion CT ICE/CECAT 21 55 28-76 0.12
Topo NB 37 83 53-93
Primary Tumor Reduction before Surgery* <50% 35 78 54-90 0.04
>50%, <90% 4 50 1-91
>90% 12 47 17-72
Surgery Radical 45 68 49-81 0.35
Not Radical 13 90 47-99
Response before HDC** CR/VGPR 21 86 62-95 <0.001
PD 11 0 -
PR 24 64 34-83
RT Yes 28 100 - <0.001
No 30 48 27-67
LEGEND: pt, patient; BX, biopsy; CR, complete remission; VGPR, very good partial remission; PD, progressive disease; PR, partial response.
*In 7 patients surgery was performed at diagnosis, one patient died for an acute bleeding after accidental removal of central vein catheter.
**Two patients were not considered for this analysis; one patient died for acute bleeding and the later one died for acute renal failure.
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3891 study compared high-dose chemotherapy followed
by ABMT with maintenance chemotherapy [3]. Recently,
Simon et al. [15] reported no impact of primary tumor
surgery on local control and survival in 278 cases of meta-
static NBL diagnosed in children over 18 months of age,
enrolled in the German clinical trial NB97 and with no
progression, relapse or death during the first 120 days of
induction chemotherapy. This study was a randomized
trial comparing high-dose chemotherapy followed by
ABMT with oral maintenance chemotherapy [4,14].
In this paper, the authors discuss whether a single-
center study or a multi-center study is the best setting
for evaluating the impact of surgery in metastatic NBL.
Probably, the single center series is more suitable for this
analysis since, in such studies, all the procedures are per-
formed by the same highly trained surgeons, thus avoid-
ing a “different degrees of surgeons’ expertise” bias.
Although the number of patients enrolled in our study
was limited, the data clearly suggest that the type of sur-
gery has no impact in terms of survival in metastatic
NBL in children over one year of age treated with high-
dose chemotherapy.
In this series, primary surgery was performed in about
10% of patients, achieving in most cases a CR of primary
tumor, whereas, after the induction phase, surgery was
performed in more than 90% of patients. Overall, radical
surgery was performed in 80% of patients. Nephrectomy –
recorded in 13% of patients - was the major complication.
The International Neuroblastoma Risk Group modified
the criteria for classification of localized NBL, including
the image-defined risk factors (IDRFs), which assess both
the staging of the tumor and the criteria for identifying
and predicting the surgical risks for vital structures
[27,28]. IDRFs could be a useful tool for the surgeon, even
for patients with metastatic high-risk NBL, in that they
predict and possibly help to avoid both acute and late
surgical complications such as renal failure after nephrec-
tomy, renal atrophy after adrenal resection, and ejacula-
tory dysfunction secondary to pelvic resection. In this
series, the same surgical team performed both the pre-
surgical patient evaluation and the surgical procedure.
The involvement of a highly-experienced surgical team
will probably result in a lower rate of post-operative com-
plications, even in patients with several surgical risk fac-
tors. As underlined by Simon [15], surgery should be
conservative and the risk of removing the kidney or any
other vital organ should be carefully weighed against any
potential benefits.
As previously reported, RT after surgery seems the
best option to control local relapse [16-18]. Our findings
confirm these previously published data since, in this co-
hort, RT was associated with a lower local recurrence
rate. Indeed, the LPFS in patients who received RT was
100% and contributed to improving the probability of
OS considering that patients who did not receive RT
had an HR of 2.36 for OS (P = 0.025).
Conclusions
In conclusion, we show that the extent of surgery had
no impact on survival in a our single center series of
homogeneously treated metastatic NBL. Surgery may
help to achieve the best disease control before high-dose
chemotherapy and should be proposed to all patients
after the induction phase; in centers with experienced
surgeons, it could be discussed at diagnosis after consid-
ering the IDRFs.
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